|
| |||||||||||||||||||||||||||||||||||||||||
Ariel Jaitovich, M.D.
Northwestern University
Chicago, IL 60611
a-jaitovich{at}northwestern.edu
References
There is currently no consensus regarding whom to test for the inherited thrombophilias. Each year, approximately 250,000 patients receive a diagnosis of acute venous thromboembolism. It has been argued that testing of all patients with an initial episode of venous thromboembolism is not cost-effective.1 For patients with an initial episode of idiopathic venous thromboembolism, routine testing for an inherited thrombophilic defect would only be warranted if the results changed the treatment approach. However, Farzaneh-Far et al. later state that they "favor providing long-term anticoagulation with warfarin." If the decision has already been made to provide long-term anticoagulation, then the clinical utility of testing for a hypercoagulable state is limited.
Marc Itskowitz, M.D.
Allegheny General Hospital
Pittsburgh, PA 15212
mitskowi{at}wpahs.org
References
Dr. Itskowitz makes an important point regarding the lack of consensus about indications for testing for inherited thrombophilias. We agree that routine testing of all patients with idiopathic venous thromboembolism is not cost-effective. However, one could argue that a patient who has an idiopathic venous thromboembolism before 50 years of age has thrombophilia, and therefore, laboratory investigation is warranted.3 Given that abnormalities predisposing patients to venous thromboembolism, including protein S deficiency, are more common in patients with HIV infection, testing a 35-year-old man with HIV is not unreasonable, albeit costly. Although long-term anticoagulation was favored in this patient regardless of the test results, because of the life-threatening nature of his pulmonary embolism, such results could influence the intensity of anticoagulation. If the patient were found to have clinically significant titers of antiphospholipid antibodies, for example, his target international normalized ratio might be higher than that of a patient without this finding.
Ramin Farzaneh-Far, M.D.
University of California, San Francisco
San Francisco, CA 94117
Talya Schwarzberg, M.D.
Beth Israel Deaconess Medical Center
Boston, MA 02215
tschwar1{at}bidmc.harvard.edu
References
| |||||||||||||||||||||||||||||||||||||||||
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |